KL

Keith Lenden

Founder of Boundless Bio

San Carlos, California

Overview 

Keith Lenden is a Venture Partner at ARCH Venture Partners, with a background in product management and entrepreneurship. He has co-founded multiple successful companies in the biopharmaceutical industry and has held leadership roles in various organizations, contributing significantly to their growth and success.

Work Experience 

  • Venture Partner

    2017 - Current

    ARCH Venture Partners is a leading biotechnology and pharmaceutical venture capital firm

ARCH is a venture firm that focuses on life science discoveries to prevent, detect, and cure disease.

  • Co-Founder

    2018

    Autobahn Therapeutics is a CNS focused drug discovery and development company founded on technology from the Oregon Health & Science University

Clinical stage biotechnology company developing restorative treatments for people affected by neuropsychiatric & neuroimmunologic disorders

Raised $208,700,000.00 from GT Healthcare Capital Partners, Samsara BioCapital, ARCH Venture Partners, Biotechnology Value Fund, Monograph Capital, Insight Partners, Newpath Management, Canaan Partners, Bristol-Myers Squibb and Pfizer Venture Investments.

  • Co-Founder

    2018

    Boundless Bio is an ecDNA focused oncology drug discovery and development company founded on technology from the Ludwig Cancer Research Institute at UCSD

Boundless Bio is a precision oncology company that develops therapeutics directed against extrachromosomal DNA in aggressive cancers.

Raised $251,400,000.00 from Nextech Invest, Piper Heartland Healthcare Capital, ARCH Venture Partners, RA Capital Management, Wellington Management, Surveyor Capital, Fidelity, Logos Capital, City Hill Ventures and Alexandria Venture Investments.

  • Co-Founder

    2011 - 2019

    Abide Therapeutics was a serine hydrolase inhibitor drug discovery and development company founded on technology from the Scripps Research Institute that was acquired by Lundbeck in 2019

  • Co-Founder

    2008 - 2015

    Receptos (NASDAQ: RCPT) was a GPCR drug discovery and development company founded on technology from the Scripps Research Institute and acquired by Celgene in 2015 (now BMS)

  • Vice President, Corporate Development & Strategy

    2013 - 2015

    Esperion Therapeutics (NASDAQ: ESPR) is a cardiovascular drug development company

  • Vice President, Product & Business Development

    2007 - 2013

    Maxygen was a biotechnology discovery and product development company

  • Senior Director, Business Development

    2004 - 2007

    Acologix was a renal focused drug development company

  • Director, Business Development

    2001 - 2004

    Genteric was a gene therapy and drug delivery company

  • Consultant

    1995 - 1999

    LEK Consulting is a leading biotechnology strategy consulting organization

Articles About Keith

Relevant Websites